tbuckley/cabot-search huggingface dataset:
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
Authors: L.-T. Chen, T.M. Macarulla, B. Belanger, B. Mirakhur, F.A. de Jong, J. Siveke
Journal: Annals of Oncology (2018)
Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients
Authors: I. Tsimafeyeu, E.N. Imyanitov, L. Zavalishina, G. Raskin, P. Povilaitite, N. Savelov, E. Kharitonova, A. Rumyantsev, I. Pugach, Y. Andreeva, A. Petrov, G. Frank, S. Tjulandin
Journal: Annals of Oncology (2018)
Surgery of the primary tumor for de novo metastatic breast cancer: The controversy continues
Authors: B. López de San Vicente, E. Galve Calvo, A. Zumarraga, F. Pikab ea, J.F. Arango Arteaga, M. López Santillan, C. Figaredo, M.A. Sala Gonzalez, M. Nuño Escolastico, P. Novas Vidal, J. Legaspi, P. Martinez del Prado
Journal: Annals of Oncology (2018)
P1.01-91 A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer
Authors: J. Surujballi, D. Breadner, D. Morris, A. O'Connor, F. Whiston, L. Sitt, M. Vincent
Journal: Journal of Thoracic Oncology (2018)
Clinical and economic burden of bloodstream infections caused by meticillin-resistant and meticillin-susceptible Staphylococcus aureus in Chinese tertiary hospitals from 2010 to 2017: a multicentre, retrospective cohort study
Authors: Haishaerjiang Wushouer, Xiaodong Guan, Sheng Han, Luwen Shi
Journal: The Lancet (2018)
Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
Authors: Peter Pickkers, Ravindra L. Mehta, Patrick T. Murray, Michael Joannidis, Bruce A. Molitoris, John A. Kellum, Mirjam Bachler, Eric A. J. Hoste, Oscar Hoiting, Kenneth Krell, Marlies Ostermann, Wim Rozendaal, Miia Valkonen, David Brealey, Albertus Beishuizen, Ferhat Meziani, Raghavan Murugan, Hilde de Geus, Didier Payen, Erik van den Berg, Jacques Arend
Journal: JAMA (2018)

Sepsis-associated acute kidney injury (AKI) adversely affects long-term kidney outcomes and survival. Administration of the detoxifying enzyme alkaline phosphatase may improve kidney function and survival.To determine the optimal therapeutic dose, effect on kidney function, and adverse effects of a human recombinant alkaline phosphatase in patients who are critically ill with sepsis-associated AKI.The STOP-AKI trial was an international (53 recruiting sites), randomized, double-blind, placebo-controlled, dose-finding, adaptive phase 2a/2b study in 301 adult patients admitted to the intensive care unit with a diagnosis of sepsis and AKI. Patients were enrolled between December 2014 and May 2017, and follow-up was conducted for 90 days. The final date of follow-up was August 14, 2017.In the intention-to-treat analysis, in part 1 of the trial, patients were randomized to receive recombinant alkaline phosphatase in a dosage of 0.4 mg/kg (n = 31), 0.8 mg/kg (n = 32), or 1.6 mg/kg (n = 29) or placebo (n = 30), once daily for 3 days, to establish the optimal dose. The optimal dose was identified as 1.6 mg/kg based on modeling approaches and adverse events. In part 2, 1.6 mg/kg (n = 82) was compared with placebo (n = 86).The primary end point was the time-corrected area under the curve of the endogenous creatinine clearance for days 1 through 7, divided by 7 to provide a mean daily creatinine clearance (AUC1-7 ECC). Incidence of fatal and nonfatal (serious) adverse events ([S]AEs) was also determined.Overall, 301 patients were enrolled (men, 70.7%; median age, 67 years [interquartile range {IQR}, 59-73]). From day 1 to day 7, median ECC increased from 26.0 mL/min (IQR, 8.8 to 59.5) to 65.4 mL/min (IQR, 26.7 to 115.4) in the recombinant alkaline phosphatase 1.6-mg/kg group vs from 35.9 mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR, 22.7 to 115.2) in the placebo group (absolute difference, 9.5 mL/min [95% CI, -23.9 to 25.5]; P = .47). Fatal adverse events occurred in 26.3% of patients in the 0.4-mg/kg recombinant alkaline phosphatase group; 17.1% in the 0.8-mg/kg group, 17.4% in the 1.6-mg/kg group, and 29.5% in the placebo group. Rates of nonfatal SAEs were 21.0% for the 0.4-mg/kg recombinant alkaline phosphatase group, 14.3% for the 0.8-mg/kg group, 25.7% for the 1.6-mg/kg group, and 20.5% for the placebo group.Among patients who were critically ill with sepsis-associated acute kidney injury, human recombinant alkaline phosphatase compared with placebo did not significantly improve short-term kidney function. Further research is necessary to assess other clinical outcomes.ClinicalTrials.gov Identifier: NCT02182440.
A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)
Authors: N. Hanai, T. Asakage, N. Kiyota, A. Homma, N. Monden, H. Fukushima, T. Fujii, T. Ogawa, K. Tanaka, J. Mizusawa, J. Eba, R. Hayashi
Journal: Annals of Oncology (2018)
Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study
Authors: N.M.L. Battisti, M. Wallington, A. Ring, S. Payne, R. Birch, M. Bomb, J. Seligmann, T. Kalsi, L. Hounsome, D. Dodwell, S. Underhill, L. Mensah, E. Morris, P.J. Selby, J. Mansi
Journal: Annals of Oncology (2018)
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial
Authors: C. Coens, A. Bottomley, C.U. Blank, M. Mandala, G.V. Long, V.G. Atkinson, S. Dalle, A. Haydon, M. Lichinitser, A. Khattak, M.S. Carlino, S.K. Sandhu, J. Larkin, S. Puig Sarda, P.A. Ascierto, D. Schadendorf, N. Ibrahim, S. Suciu, C. Robert, A.M.M. Eggermont
Journal: Annals of Oncology (2018)
ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort
Authors: T. Aparicio, S. Manfredi, D. Tougeron, J. Henriques, O. Bouche, D. Pezet, G. Piessen, R. Coriat, A. Zaanan, J.L. Legoux, E. Terrebone, M. Pocard, J.-M. Gornet, D. Vernerey, P. Afchain
Journal: Annals of Oncology (2018)
P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study)
Authors: J.B. Auliac, M. Pérol, D. Planchard, I. Monnet, M. Wislez, H. Doubre, F. Guisier, E. Pichon, L. Greillier, B. Mastroianni, C. Decroissette, R. Schott, S. Le Moulec, J. Arrondeau, A. Cortot, L. Gerinière, A. Renault, C. Daniel, L. Falchero, C. Chouaid
Journal: Journal of Thoracic Oncology (2018)
Danish-like Regulations May Improve Postabortion Mental Health Risk—Reply
Authors: Julia R. Steinberg, Nancy E. Adler, Trine Munk-Olsen
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
Authors: M.J. Jimenez Exposito, M. Akce, J.L. Montero Alvarez, E. Assenat, L.A. Balart, A.D. Baron, T. Decaens, A. Heurgue-Berlot, A.O. Martin, S.W. Paik, V. Poulart, A.S. Sehbai, N. Takemura, J.-H. Yoon
Journal: Annals of Oncology (2018)
P1.17-16 Correlation of Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy with Pathological Complete Response of Lung Cancer
Authors: S. Takahashi, T. Go, T. Nishide, M. Anada, T. Kinoshita, H. Yokomise, T. Shibata
Journal: Journal of Thoracic Oncology (2018)
CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma
Authors: E.J. Lipson, G.V. Long, H. Tawbi, D. Schadendorf, V.G. Atkinson, M. Maurer, K.L. Simonsen, C. Harbison, F.S. Hodi
Journal: Annals of Oncology (2018)
Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC)
Authors: M. Jahanzeb, H.M. Lin, X. Pan, Y. Yin, P. Hou, B.L. Nordstrom, A. Desai, M.A. Socinski
Journal: Annals of Oncology (2018)
Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Authors: R.S. Finn, M. Kudo, A.-L. Cheng, L. Wyrwicz, R. Ngan, J.F. Blanc, A.D. Baron, A. Vogel, M. Ikeda, F. Piscaglia, K.-H. Han, S. Qin, Y. Minoshima, M. Kanekiyo, M. Ren, R. Dairiki, T. Tamai, C.E. Dutcus, Y. Funahashi, T.R.J. Evans
Journal: Annals of Oncology (2018)
Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations
Authors: J.J. Luke, R. Edwards, C. Hedvat, D. Pandya, S. Ely, R. Meier, D. McDonald, C.T. Harbison, V. Baxi, G. Lee, P. Szabo, T. Garcia, R. Bao, T.P. Reilly, E. Jaffee, F.S. Hodi
Journal: Annals of Oncology (2018)
Regorafenib for metastatic colorectal carcinoma: A registry-based analysis
Authors: K. Kopeckova, R. Chloupkova, B. Melichar, Z. Linke, L.B. Petruzelka, J. Finek, O. Fiala, J. Tomasek, I. Kiss, J. Prausova, T. Buchler
Journal: Annals of Oncology (2018)
P2.01-20 FLT-PET for Detection of Relapse Following Radiotherapy for Lung Cancer. Preliminary Results
Authors: T. Christensen, S. Langer, K. Larsen, G. Persson, A. Amtoft, H. Johannesen, S. Keller, A. Kjaer, B. Fischer
Journal: Journal of Thoracic Oncology (2018)
STELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma
Authors: F. Grosso, J.G. Aerts, J. Madrzak, R. Dziadziuszko, R. Ramlau, S. Cedres, B. Hiddinga, J.P. van Meerbeeck, M. Mencoboni, D. Planchard, A. Chella, L. Crino, M.J. Krzakowski, G.L. Ceresoli
Journal: Annals of Oncology (2018)
Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia
Authors: T. Decker, A. Mündlein, N. Marschner, A. Welt, T. Riedt, V. Hagen, J. Rauh, D. Klein, K. Potthoff, P. Jähnig, H. Schröder, S. Hegewisch-Becker, C. Lerchenmüller
Journal: Annals of Oncology (2018)
Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving fluropyrimidines and/or irinotecan-based therapy
Authors: A. Sharma, S.P. Chaudhary, V. Raina, N.K. Shukla, V. Sreenivas, S. Prakash, P. Priyatma, S. Bharti
Journal: Annals of Oncology (2018)
Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)
Authors: R. Pihlak, R. Almond, P. Srivastava, H. Raja, R. Broadbent, L. Hopewell, C. Higham, A. Lamarca, R. Hubner, J.W. Valle, M.G. McNamara
Journal: Annals of Oncology (2018)
P1.15-12 Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population
Authors: J. Kratz, G. Harmon, D. Kosoff, D. Wubben, R. Laughlin, A. Traynor, D. Deming, M. Burkard, T. Leal
Journal: Journal of Thoracic Oncology (2018)
Identification and validation of two peptide markers for the recognition of Clostridioides difficile MLST-1 and MLST-11 by MALDI-MS
Authors: J. Corver, J. Sen, B.V.H. Hornung, B.J. Mertens, E.K.L. Berssenbrugge, C. Harmanus, I.M.J.G. Sanders, N. Kumar, T.D. Lawley, E.J. Kuijper, P.J. Hensbergen, S. Nicolardi
Journal: Clinical Microbiology and Infection (2018)
P2.10-05 Provider Medical Specialty Influences Smoking Cessation Counseling at an Academic Medical Center and Veterans Affairs in U.S. Mid-South
Authors: J. Lewis, H. Chen, K. Weaver, L. Spalluto, K. Sandler, L. Horn, R. Dittus, P. Massion, C. Roumie, H. Tindle
Journal: Journal of Thoracic Oncology (2018)
Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury
Authors: Stéphanie Debette, Sabrina Schilling, Marie-Gabrielle Duperron, Susanna C. Larsson, Hugh S. Markus
Journal: JAMA Neurology (2018)

Covert vascular brain injury (VBI) is highly prevalent in community-dwelling older persons, but its clinical and therapeutic implications are debated.To better understand the clinical significance of VBI to optimize prevention strategies for the most common age-related neurological diseases, stroke and dementia.We searched for articles in PubMed between 1966 and December 22, 2017, studying the association of 4 magnetic resonance imaging (MRI) markers of covert VBI (white matter hyperintensities [WMHs] of presumed vascular origin, MRI-defined covert brain infarcts [BIs], cerebral microbleeds [CMBs], and perivascular spaces [PVSs]) with incident stroke, dementia, or death.Data were taken from prospective, longitudinal cohort studies including 50 or more adults.We performed inverse variance-weighted meta-analyses with random effects and z score-based meta-analyses for WMH burden. The significance threshold was P < .003 (17 independent tests). We complied with the Meta-analyses of Observational Studies in Epidemiology guidelines.Stroke (hemorrhagic and ischemic), dementia (all and Alzheimer disease), and death.Of 2846 articles identified, 94 studies were eligible, with up to 14 529 participants for WMH, 16 012 participants for BI, 15 693 participants for CMB, and 4587 participants for PVS. Extensive WMH burden was associated with higher risk of incident stroke (hazard ratio [HR], 2.45; 95% CI, 1.93-3.12; P < .001), ischemic stroke (HR, 2.39; 95% CI, 1.65-3.47; P < .001), intracerebral hemorrhage (HR, 3.17; 95% CI, 1.54-6.52; P = .002), dementia (HR, 1.84; 95% CI, 1.40-2.43; P < .001), Alzheimer disease (HR, 1.50; 95% CI, 1.22-1.84; P < .001), and death (HR, 2.00; 95% CI, 1.69-2.36; P < .001). Presence of MRI-defined BIs was associated with higher risk of incident stroke (HR, 2.38; 95% CI, 1.87-3.04; P < .001), ischemic stroke (HR, 2.18; 95% CI, 1.67-2.85; P < .001), intracerebral hemorrhage (HR, 3.81; 95% CI, 1.75-8.27; P < .001), and death (HR, 1.64; 95% CI, 1.40-1.91; P < .001). Presence of CMBs was associated with increased risk of stroke (HR, 1.98; 95% CI, 1.55-2.53; P < .001), ischemic stroke (HR, 1.92; 95% CI, 1.40-2.63; P < .001), intracerebral hemorrhage (HR, 3.82; 95% CI, 2.15-6.80; P < .001), and death (HR, 1.53; 95% CI, 1.31-1.80; P < .001). Data on PVS were limited and insufficient to conduct meta-analyses but suggested an association of high PVS burden with increased risk of stroke, dementia, and death; this requires confirmation.We report evidence that MRI markers of VBI have major clinical significance. This research prompts careful evaluation of the benefit-risk ratio for available prevention strategies in individuals with covert VBI.
Canonical and single-cell Hi-C reveal distinct chromatin interaction sub-networks of mammalian transcription factors
Authors: Xiaoyan Ma, Daphne Ezer, Boris Adryan, Tim J. Stevens
Journal: Genome biology (2018)

Transcription factor (TF) binding to regulatory DNA sites is a key determinant of cell identity within multi-cellular organisms and has been studied extensively in relation to site affinity and chromatin modifications. There has been a strong focus on the inference of TF-gene regulatory networks and TF-TF physical interaction networks. Here, we present a third type of TF network, the spatial network of co-localized TF binding sites within the three-dimensional genome. Using published canonical Hi-C data and single-cell genome structures, we assess the spatial proximity of a genome-wide array of potential TF-TF co-localizations in human and mouse cell lines. For individual TFs, the abundance of occupied binding sites shows a positive correspondence with their clustering in three dimensions, and this is especially apparent for weak TF binding sites and at enhancer regions. An analysis between different TF proteins identifies significantly proximal pairs, which are enriched in reported physical interactions. Furthermore, clustering of different TFs based on proximity enrichment identifies two partially segregated co-localization sub-networks, involving different TFs in different cell types. Using data from both human lymphoblastoid cells and mouse embryonic stem cells, we find that these sub-networks are enriched within, but not exclusive to, different chromosome sub-compartments that have been identified previously in Hi-C data. This suggests that the association of TFs within spatial networks is closely coupled to gene regulatory networks. This applies to both differentiated and undifferentiated cells and is a potential causal link between lineage-specific TF binding and chromosome sub-compartment segregation.
Antiphospholipid Antibodies in Patients With Myocardial Infarction
Authors: Giorgia Grosso, Natalie Sippl, Barbro Kjellström, Khaled Amara, Ulf de Faire, Kerstin Elvin, Bertil Lindahl, Per Näsman, Lars Rydén, Anna Norhammar, Elisabet Svenungsson
Journal: Annals of Internal Medicine (2018)

Background: Antiphospholipid syndrome (APS) is defined by arterial, venous, or microvascular thrombosis or obstetric morbidity together with confirmed positive test results, at least 12 weeks apart ...
Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer
Authors: N. Pecuchet, R. Touachi, A. Ben Lakhdar, V. Fallet, N. Rabbe, H. Blons, A. Lemoine, M. Antoine, S. Tenam, P. Laurent-Puig, M. Wislez
Journal: Annals of Oncology (2018)
Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma
Authors: Lei Huang, Sarah Garrett Injac, Kemi Cui, Frank Braun, Qi Lin, Yuchen Du, Huiyuan Zhang, Mari Kogiso, Holly Lindsay, Sibo Zhao, Patricia Baxter, Adesina Adekunle, Tsz-Kwong Man, Hong Zhao, Xiao-Nan Li, Ching C. Lau, Stephen T. C. Wong
Journal: Science Translational Medicine (2018)

Systematic drug repositioning identifies digoxin as a potential treatment for groups 3 and 4 medulloblastoma.
MA04.07 MicroRNA-Based Liquid Biopsy Combines with PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients
Authors: M. Boeri, M. Milione, D. Signorelli, C. Proto, G. Lo Russo, C. Galeone, G. Centonze, U. Pastorino, M. Garassino, G. Sozzi
Journal: Journal of Thoracic Oncology (2018)
Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles
Authors: Christian J. Konopka, Marcin Wozniak, Jamila Hedhli, Agata Ploska, Aaron Schwartz-Duval, Anna Siekierzycka, Dipanjan Pan, Gnanasekar Munirathinam, Iwona T. Dobrucki, Leszek Kalinowski, Lawrence W. Dobrucki
Journal: Theranostics (2018)

The receptor for advanced glycation end-products (RAGE) is central to multiple disease states, including diabetes-related conditions such as peripheral arterial disease (PAD).Despite RAGE's importance in these pathologies, there remains a need for a molecular imaging agent that can accurately assess RAGE levels in vivo.Therefore, we have developed a multimodal nanoparticle-based imaging agent targeted at RAGE with the well-characterized RAGE ligand, carboxymethyllysine (CML)-modified human serum albumin (HSA).Methods: A multimodal tracer ( 64 Cu-Rho-G4-CML) was developed using a generation-4 (G4) polyamidoamine (PAMAM) dendrimer, conjugated with both rhodamine and copper-64 ( 64 Cu) chelator (NOTA) for optical and PET imaging, respectively.First, 64 Cu-Rho-G4-CML and its non-targeted analogue ( 64 Cu-Rho-G4-HSA) were evaluated chemically using techniques such as dynamic light scattering (DLS), electron microscopy and nuclear magnetic resonance (NMR).The tracers' binding capabilities were examined at the cellular level and optimized using live and fixed HUVEC cells grown in 5.5-30 mM glucose, followed by in vivo PET-CT imaging, where the probes' kinetics, biodistribution, and RAGE targeting properties were examined in a murine model of hindlimb ischemia.Finally, histological assessment of RAGE levels in both ischemic and non-ischemic tissues was performed.Conclusions: Our RAGE-targeted probe demonstrated an average size of 450 nm, a Kd of 340-390 nM, rapid blood clearance, and a 3.4 times greater PET uptake in ischemic RAGE-expressing hindlimbs than their non-ischemic counterpart.We successfully demonstrated increased RAGE expression in a murine model of hindlimb ischemia and the feasibility for non-invasive examination of cellular, tissue, and whole-body RAGE levels with a molecularly targeted tracer.
P2.06-38 Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure
Authors: L. Wu, M. Chan, T. Mckee, S. Butt, M. Cabanero, B. Green, B. Duong, Z. Yun, M. Kohno, J. Murakami, Y. Zhao, S. Kelley, M. De Perrot
Journal: Journal of Thoracic Oncology (2018)
Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected endometrial cancer (EC) patients
Authors: C.M.A. Orbegoso Aguilar, K. Vroobel, S. Lalondrelle, A. Taylor, M. Nobbenhuis, A. Attygalle, S. Banerjee, A. George
Journal: Annals of Oncology (2018)
P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
Authors: G. Rossi, M. Tagliamento, A. Alama, S. Coco, C. Genova, E. Rijavec, G. Barletta, F. Biello, I. Vanni, S. Boccardo, M.G. Dal Bello, R. Alessandra, V. Fontana, F. Grossi
Journal: Journal of Thoracic Oncology (2018)
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
Authors: J. Weber, G.V. Long, J.B. Haanen, A. Arance, R. Dummer, P. Nathan, A. Ribas, P.A. Ascierto, C. Robert, E. Gasal, A. D’Amelio, S. Bettinger, A.D. Boran, D. Schadendorf
Journal: Annals of Oncology (2018)
Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial
Authors: A.E. Slagter, K. Sikorska, C. Grootscholten, H.W.M. van Laarhoven, H. Boot, E. Meershoek-Klein Kranenbarg, C.J.H. van de Velde, N.C. van Grieken, E.P.M. Jansen, M. Verheij, A. Cats
Journal: Annals of Oncology (2018)
P2.12-04 Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
Authors: L. Paz-Ares, J.C. Yang, C. Zielinski, S. Novello, G. Schwartsmann, D. Spigel, F. Griesinger, A. Dowlati, T. Small, F. De Jong, B. Zhang, N. Nazarenko, P. Bunn
Journal: Journal of Thoracic Oncology (2018)
OA10.07 Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial
Authors: C. Zhou, M. Hu, X. Zhu, Y. Sun, X. Lu, J. Wang, M. Wang, Y. Cheng, Y. Chen, Y. Zhao, Y. Shi, Y. Lu, M. Shi, H. Zhang, X. Huang, Z. Wang, Z. Ding, H. Li, G. Chen, Y. Wu
Journal: Journal of Thoracic Oncology (2018)